Document Actions
Publicações
Up one levelImmunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune® vaccine
20/9-/5-01 13h34
Participation of Rhipicephalus sanguineus (Acari: Ixodidae) in the epidemiology of canine visceral leishmaniasis
20/9-/5-01 13h31
Pulcherrimasaponin, from the leaves of Calliandra pulcherrima, as adjuvant for immunization in the murine model of visceral leishmaniasis
20/9-/5-01 13h29
Leishmune1 vaccine: The newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine
20/9-/5-01 13h27
LEISHIMUNE VACCINE-INDUCED IMMUNE RESPONSE IN DOGS FROM AN ENDEMIC AREA OF VISCERAL LEIHMANIASIS
20/9-/5-01 13h26
Investigação De Ctenocephalides Felis Como Vetor De Leishmania spp. Research On Ctenocephalides Felis As A Vector Of Leishmania spp.
20/9-/5-01 13h25
THE FUCOSE-MANNOSE LIGAND–ELISA IN THE DIAGNOSIS AND PROGNOSIS OF CANINE VISCERAL LEISHMANIASIS IN BRAZIL
20/9-/5-01 13h23
Reflexões sobre a qualidade do diagnóstico da leishmaniose visceral canina em inquéritos epidemiológicos: o caso da epidemia de Belo Horizonte, Minas Gerais, Brasil, 1993-1997
20/9-/5-01 13h22
Nucleoside hydrolase from Leishmania (L.) donovani is an antigen diagnostic for visceral leishmaniasis
20/9-/5-01 13h20
Improving methods for epidemiological control of canine visceral leishmaniasis based on a mathematical model. Impact on the incidence of the canine and human disease
20/9-/5-01 13h19
Clinical value of anti-Leishmania (Leishmania) chagasi IgG titers detected by flow cytometry to distinguish infected from vaccinated dogs
20/9-/5-01 13h16
Evaluation of the conjunctival swab for canine visceral leishmaniasis diagnosis by PCR–hybridization in Minas Gerais State, Brazil
20/9-/5-01 13h13
Safety trial using the Leishmune® vaccine against canine visceral leishmaniasis in Brazil
20/9-/5-01 13h11
Immunogenicity assay of the Leishmune® vaccine against canine visceral leishmaniasis in Brazil
20/9-/5-01 13h10
FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine
20/9-/5-01 13h07
The FML-vaccine (Leishmune®) against canine visceral leishmaniasis: A transmission blocking vaccine
20/9-/5-01 13h05
Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN)
20/9-/5-01 13h04
Leishmune® vaccine blocks the transmission of canine visceral leishmaniasis Absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs
20/9-/5-01 13h04
A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN)
20/9-/5-01 13h02
Vaccination of Swiss Albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani
20/9-/5-01 13h01
Vaccination of Balb:c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani
20/9-/5-01 12h59
The FML vaccine (fucose-mannose ligand) protects hamsters from experimental kala-azar
20/9-/5-01 12h55
Protective vaccination against murine visceral leishmaniasis using aldehyde-containing Quillaja saponaria sapogenins
20/9-/5-01 12h54
IgG1/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniosis
20/9-/5-01 12h47
Experimental murine Leishmania donovani infection: immunoprotection by the fucose-mannose ligand (FML)
20/9-/5-01 12h44
Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis
20/9-/5-01 12h41
